Weight-loss and diabetes drugs reduced the risk of developing Alzheimer’s, an independent study published Monday showed.The ...

Eli Lilly (LLY 1.45%) began a roll in late 2020 that lasted almost four years. During that time, it became the world's ...

The Baltimore City Board of School Commissioners is suing Eli Lilly and Co., UnitedHealth Group, CVS and several other drug ...

Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December ...

The technical picture worsened for Eli Lilly stock in December as it completed a pattern known as a “Death Cross”. This ...

Eli Lilly shares fell after the drugmaker warned that sales of its hot diabetes and anti-obesity drugs are growing more slowly than expected. Lilly now expects fourth-quarter sales of $3.5 billion for ...

A Medscape survey found that a strong majority of physicians believe high-risk patients should have easier access to new weight loss drugs.

Eli Lilly & Co. ( LLY) thinks its next experimental weight-loss pill could get approved as soon as early 2026.

Eli Lilly is leading a push with other pharmaceutical ... targeted in the next round are Novo Nordisk's popular diabetes and weight loss medications, Ozempic and Wegovy, according to Bloomberg.

for both drugs, indicating strong market acceptance and potential for continued revenue growth. The success of these GLP-1 receptor agonists has positioned Eli Lilly as a leader in the diabetes ...

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has ...

for both drugs, indicating strong market acceptance and potential for continued revenue growth. The success of these GLP-1 receptor agonists has positioned Eli Lilly as a leader in the diabetes and ...